Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Trial to Evaluate the Benefit of Adding Octreotide (SMS 201-995 PA LAR) to Tamoxifen Alone or to Tamoxifen and Chemotherapy in Patients With Axillary Node-Negative, Estrogen-Receptor-Positive, Primary Invasive Breast Cancer

NCT00002967 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT00002967
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00002967 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Trial to Evaluate the Benefit of Adding Octreotide (SMS 201-995 PA LAR) to Tamoxifen Alone or to Tamoxifen and Chemotherapy in Patients With Axillary Node-Negative, Estrogen-Receptor-Positive, Primary Invasive Breast Cancer
Lead sponsor
NSABP Foundation Inc
Phase
Phase 3
Overall status
Completed
Start date
May 31, 1997
Completion date
March 31, 2006
Enrollment
Not reported
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer